<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548246" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548246/" /><meta name="ncbi_pagename" content="Penicillamine - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Penicillamine - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Penicillamine" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/07/25" /><meta name="citation_pmid" content="31643570" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548246/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Penicillamine" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/07/25" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548246/" /><meta name="description" content="Penicillamine is chelating agent used to decrease copper stores in Wilson disease, which also has immunomodulatory activity in rheumatic diseases such as rheumatoid arthritis, scleroderma and systemic lupus erythematosus. Penicillamine is capable of causing hypersensitivity reactions, some of which are accompanied by liver injury which is typically cholestatic." /><meta name="og:title" content="Penicillamine" /><meta name="og:type" content="book" /><meta name="og:description" content="Penicillamine is chelating agent used to decrease copper stores in Wilson disease, which also has immunomodulatory activity in rheumatic diseases such as rheumatoid arthritis, scleroderma and systemic lupus erythematosus. Penicillamine is capable of causing hypersensitivity reactions, some of which are accompanied by liver injury which is typically cholestatic." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548246/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Penicillamine/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548246/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D209D046645F100000000093302B8.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548246_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548246_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Penbutolol/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/PenicilllinGandV/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548246_"><span class="title" itemprop="name">Penicillamine</span></h1><p class="small">Last Update: <span itemprop="dateModified">July 25, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Penicillamine.OVERVIEW"><h2 id="_Penicillamine_OVERVIEW_">OVERVIEW</h2><div id="Penicillamine.Introduction"><h3>Introduction</h3><p>Penicillamine is chelating agent used to decrease copper stores in <a class="def" href="/books/n/livertox/glossary/def-item/glossary.wilson-disease/">Wilson disease</a>, which also has immunomodulatory activity in rheumatic diseases such as rheumatoid arthritis, scleroderma and systemic lupus erythematosus. Penicillamine is capable of causing hypersensitivity reactions, some of which are accompanied by liver injury which is typically cholestatic.</p></div><div id="Penicillamine.Background"><h3>Background</h3><p>Penicillamine (pen" i sil' a meen) is d-isomer of dimethylcysteine, a breakdown product of penicillin, which was originally isolated from the urine of patients with liver disease receiving penicillin. It was later found to have chelating properties against copper and used in <a class="def" href="/books/n/livertox/glossary/def-item/glossary.wilson-disease/">Wilson disease</a>. Penicillamine was also found to lower levels of immune complexes, which led to its use in several rheumatic and immune disorders such as rheumatoid arthritis, scleroderma, systemic lupus erythematosus and primary biliary cirrhosis. Penicillamine was approved for use in Wilson disease in 1960 and is still widely used for that rare indication. The use of penicillamine for rheumatic disorders has decreased markedly with the availability of more modern, potent and less toxic agents. Penicillamine is available in generic forms and under the brand names of Cuprimine and Depen in capsules of 125 and 250 mg and tablets of 250 mg. The usual dose in 250 mg four times daily, increasing based upon effect and tolerance to a maximum of 2 grams daily. Lower doses were used in rheumatic diseases. Common side effects include gastrointestinal upset, metallic taste, bone marrow suppression, rash, pruritus, induction of autoimmune diseases and drug fever. Severe adverse events include aplastic anemia, agranulocytosis, thrombocytopenia, renal dysfunction, proteinuria, Goodpasture syndrome, myasthenia gravis, pemphigus and acute hypersensitivity reactions.</p></div><div id="Penicillamine.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Penicillamine has been linked to a characteristic pattern of liver injury arising 1 to 6 weeks after starting therapy, with a distinctly cholestatic pattern of serum enzyme elevations (Case 1). The jaundice due to penicillamine can be severe and prolonged and result in protracted, symptomatic cholestasis, but most cases are self-limited. Immunoallergic manifestations of rash, fever and eosinophilia are common, but not invariable. Interesting, most cases of acute liver injury attributed to penicillamine were reported in patients with rheumatic diseases, only rare instances being reported in <a class="def" href="/books/n/livertox/glossary/def-item/glossary.wilson-disease/">Wilson disease</a>.</p><p>Other toxicities of penicillamine therapy such as bone marrow suppression, neutropenia and severe dermatologic features can accompany the hepatic injury. Furthermore, in instances with severe nonhepatic penicillamine toxicities, some degree of hepatic involvement such as mild-to-moderate serum enzyme elevations may occur. Long term toxicities of penicillamine include induction of autoimmune conditions (glomerulonephritis, pneumonitis, lupus-like syndrome) that may be accompanied by autoantibody formation, but autoimmune hepatitis-like syndromes have not been reported.</p><p>Likelihood score: A (well established cause of clinically apparent liver injury).</p></div><div id="Penicillamine.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The liver injury caused by penicillamine appears to be due to hypersensitivity as shown by its brief latency and the frequency of immunoallergic symptoms and signs. Susceptibility to penicillamine hypersensitivity has been linked to HLA DR3, sulphoxidation status and previous gold allergy, but these factors have not been specifically linked to hepatotoxicity from penicillamine.</p></div><div id="Penicillamine.Outcome_and_Management"><h3>Outcome and Management</h3><p>The hepatotoxicity of penicillamine is typically self-limited, although recovery may be delayed. However, there have been several instances of progressive cholestasis resulting in death or need for liver transplantation arising after acute, severe cholestatic liver injury due to penicillamine. While the pathology of these cases has stressed the chronic cholestatic features and progressive fibrosis, there is little information on bile duct injury and loss. Nevertheless, these instances probably represent vanishing bile duct syndrome. Monitoring of routine liver tests is recommended before and every 6 months during therapy with penicillamine. While ursodiol and corticosteroids are often used in patients with prolonged cholestasis after hepatotoxicity from penicillamine (and other drugs), there is little evidence that they are beneficial. There may be cross reactivity between penicillamine hypersensitivity and allergic responses to penicillin, but this is not invariable. Nevertheless, caution should be employed in use of penicillins in patients with severe penicillamine hypersensitivity.</p><p>Drug Class: <a href="/books/n/livertox/AntirheumaticAgents/">Antirheumatic Agents</a>; <a href="/books/n/livertox/ChelatingAgents/">Chelating Agents</a>, <a href="/books/n/livertox/WilsonDiseaseAgents/">Wilson Disease Agents</a></p><p>Other Drugs in the Subclass, Wilson Disease: <a href="/books/n/livertox/Dimercaprol/">Dimercaprol</a>, <a href="/books/n/livertox/Trientine/">Trientine</a>, <a href="/books/n/livertox/Zinc/">Zinc</a></p></div></div><div id="Penicillamine.CASE_REPORT"><h2 id="_Penicillamine_CASE_REPORT_">CASE REPORT</h2><div id="Penicillamine.Case_1_Immunoallergic_hepa"><h3>Case 1. Immunoallergic hepatitis due to penicillamine.(<a class="bk_pop" href="#Penicillamine.REF.1">1</a>)</h3><p>A 58 year old woman with scleroderma accompanied by arthritis, Raynaud&#x02019;s phenomenon, skin tightening over the face and hands, and lung involvement was placed on penicillamine in a dose of 1.8 g daily. Three weeks later she developed fever and generalized maculopapular rash, followed two days later by dark urine and jaundice. All medications were stopped. She had no previous history of liver disease or drug allergies and did not drink alcohol. Over-the-counter medications included vitamins only. Laboratory testing showed serum bilirubin of 7.4 mg/dL, mild <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations (90 U/L), and marked increases in alkaline phosphatase levels (Table). She had mild eosinophilia (5%) and leukocytosis. Over the next few days, fever and rash resolved and 3 weeks after onset, laboratory tests had returned to normal or near normal.</p><div id="Penicillamine.Key_Points"><h4>Key Points</h4><div id="Penicillamine.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548246/table/Penicillamine.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Penicillamine.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_Penicillamine.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Penicillamine.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Penicillamine (1.8 g daily)</td></tr><tr><th id="hd_b_Penicillamine.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Penicillamine.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cholestatic (R=0.3)</td></tr><tr><th id="hd_b_Penicillamine.Tc_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Penicillamine.Tc_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2+ (jaundice, not hospitalized)</td></tr><tr><th id="hd_b_Penicillamine.Tc_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Penicillamine.Tc_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 weeks</td></tr><tr><th id="hd_b_Penicillamine.Tc_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Penicillamine.Tc_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3 weeks</td></tr><tr><th id="hd_b_Penicillamine.Tc_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Penicillamine.Tc_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vitamin B6</td></tr></tbody></table></div></div></div><div id="Penicillamine.Laboratory_Values"><h4>Laboratory Values</h4><div id="Penicillamine.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548246/table/Penicillamine.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Penicillamine.Td_lrgtbl__"><table><thead><tr><th id="hd_h_Penicillamine.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Starting</th><th id="hd_h_Penicillamine.Td_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Stopping</th><th id="hd_h_Penicillamine.Td_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a><br />(U/L)</th><th id="hd_h_Penicillamine.Td_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P<br />(BEU/L)</th><th id="hd_h_Penicillamine.Td_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a><br />(mg/dL)</th><th id="hd_h_Penicillamine.Td_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Penicillamine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre</td><td headers="hd_h_Penicillamine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre</td><td headers="hd_h_Penicillamine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">19</td><td headers="hd_h_Penicillamine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.1</td><td headers="hd_h_Penicillamine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">&#x0003c;1.0</td><td headers="hd_h_Penicillamine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Penicillamine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14 days</td><td headers="hd_h_Penicillamine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Penicillamine.Td_1_1_1_3 hd_h_Penicillamine.Td_1_1_1_4 hd_h_Penicillamine.Td_1_1_1_5 hd_h_Penicillamine.Td_1_1_1_6" colspan="4" rowspan="1" style="text-align:center;vertical-align:top;">Worsening fever over 4 days followed by rash and jaundice</td></tr><tr><td headers="hd_h_Penicillamine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24 days</td><td headers="hd_h_Penicillamine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0</td><td headers="hd_h_Penicillamine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">90</td><td headers="hd_h_Penicillamine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">33.4</td><td headers="hd_h_Penicillamine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7.4</td><td headers="hd_h_Penicillamine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5% eosinophils</td></tr><tr><td headers="hd_h_Penicillamine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26 days</td><td headers="hd_h_Penicillamine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 days</td><td headers="hd_h_Penicillamine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">43</td><td headers="hd_h_Penicillamine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">32.4</td><td headers="hd_h_Penicillamine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5.8</td><td headers="hd_h_Penicillamine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Penicillamine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33 days</td><td headers="hd_h_Penicillamine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9 days</td><td headers="hd_h_Penicillamine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">21</td><td headers="hd_h_Penicillamine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">14.5</td><td headers="hd_h_Penicillamine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.6</td><td headers="hd_h_Penicillamine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Penicillamine.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39 days</td><td headers="hd_h_Penicillamine.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15 days</td><td headers="hd_h_Penicillamine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9</td><td headers="hd_h_Penicillamine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7.8</td><td headers="hd_h_Penicillamine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.9</td><td headers="hd_h_Penicillamine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Penicillamine.Td_1_1_1_1 hd_h_Penicillamine.Td_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Penicillamine.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">&#x0003c;30</td><td headers="hd_h_Penicillamine.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">&#x0003c;4.5</td><td headers="hd_h_Penicillamine.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">&#x0003c;1.2</td><td headers="hd_h_Penicillamine.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Penicillamine.Comment"><h4>Comment</h4><p>An early report without viral serology to exclude acute viral hepatitis or modern imaging to exclude biliary obstruction, but the progression of symptoms and laboratory test abnormalities were very typical of drug induced hypersensitivity and liver injury. The latency to onset of symptoms of fever, rash and malaise was 2 to 3 weeks, with jaundice appearing soon thereafter. Immunoallergic symptoms and signs were present and the pattern of serum enzyme elevations was distinctly cholestatic, features that are typical of penicillamine induced liver injury. The features of hypersensitivity usually resolve within a week of stopping therapy, whereas the cholestasis and jaundice are slower to improve. Corticosteroids appear to improve the immunoallergic symptoms and signs promptly, but their effect on the liver injury is less clear.</p></div></div></div><div id="Penicillamine.PRODUCT_INFORMATION"><h2 id="_Penicillamine_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Penicillamine &#x02013; Generic, Cuprimine&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antirheumatic Agents</p><p>Chelating Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Penicillamine" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Penicillamine.CHEMICAL_FORMULA_AND_STRUC"><h2 id="_Penicillamine_CHEMICAL_FORMULA_AND_STRUC_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Penicillamine.Te" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548246/table/Penicillamine.Te/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Penicillamine.Te_lrgtbl__"><table><tbody><tr><th id="hd_b_Penicillamine.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_b_Penicillamine.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_b_Penicillamine.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_b_Penicillamine.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr><tr><td headers="hd_b_Penicillamine.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Penicillamine</td><td headers="hd_b_Penicillamine.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134970687" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">52-67-5</a></td><td headers="hd_b_Penicillamine.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C5-H11-N-O2-S</td><td headers="hd_b_Penicillamine.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134970687" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134970687" alt="image 134970687 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="Penicillamine.CITED_REFERENCE"><h2 id="_Penicillamine_CITED_REFERENCE_">CITED REFERENCE</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="Penicillamine.REF.1">Rau R, Weber S, B&#x000f6;ni A. <span><span class="ref-journal">Schweiz Med Wochenschr. </span>1972;<span class="ref-vol">102</span>:1226–8.</span> [Allergic-toxic liver damage due to D-penicillamine] German. [<a href="/pubmed/5055042" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5055042</span></a>]</div></dd></dl></div><div id="Penicillamine.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Penicillamine_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 25 July 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Penicillamine.REF.zimmerman.1999">Zimmerman HJ. Drugs used in rheumatic diseases: penicillamine. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 542.<div><i>(Expert review of hepatotoxicity published in 1999; mentions that there have been 18 published cases of jaundice due to penicillamine, almost all cholestatic with latency of 2-4 weeks and features of hypersensitivity).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.byrns.2018">Byrns MC, Penning TM. Treatment of metal exposure. Environmental toxicology: carcinogens and heavy metals. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1311-5.</div></li><li><div class="bk_ref" id="Penicillamine.REF.walshe.1956.487">Walshe JM. Penicillamine, a new oral therapy for Wilson's disease. <span><span class="ref-journal">Am J Med. </span>1956;<span class="ref-vol">21</span>:487–95.</span> [<a href="/pubmed/13362281" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13362281</span></a>]<div><i>(Initial studies on efficacy of oral penicillamine [&#x003b2;,&#x003b2;-dimethyl cysteine, a monothiol] in inducing cupruresis in Wilson disease and lack of effect of cysteine and methionine; no toxic reactions were observed).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.walshe.1968.6">Walshe JM. Toxic reactions to penicillamine in patients with Wilson&#x02019;s disease. <span><span class="ref-journal">Postgrad Med J. </span>1968 Suppl:6–8.</span> [<a href="/pubmed/5706614" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5706614</span></a>]<div><i>(Summary of side effects of penicillamine representing 126 patient years of use in Wilson disease; important toxicities included nephrotic syndrome, lupus-like syndrome, thrombocytopenia, urticaria and one case of a 9 year old with urticaria, fever, malaise and jaundice, with positive rechallenge and inability to tolerate the drug and resultant death from Wilson disease).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.sternlieb.1968.352">Sternlieb I, Scheinberg IH. Prevention of Wilson's disease in asymptomatic patients. <span><span class="ref-journal">N Engl J Med. </span>1968;<span class="ref-vol">278</span>:352–9.</span> [<a href="/pubmed/5635646" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5635646</span></a>]<div><i>(Among 42 asymptomatic persons who were diagnosed with Wilson disease and treated with penicillamine for up to 8 years, none developed symptomatic disease).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.rau.1972.1226">Rau R, Weber S, B&#x000f6;ni A. <span><span class="ref-journal">Schweiz Med Wochenschr. </span>1972;<span class="ref-vol">102</span>:1226–8.</span> [Allergic-toxic liver damage due to D-penicillamine] German. [<a href="/pubmed/5055042" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5055042</span></a>]<div><i>(58 year old with scleroderma developed fever, rash and jaundice 2-3 weeks after starting penicillamine with bilirubin 7.4 mg/dL, ALT 90 U/L, Alk P 8 times ULN, with resolution within 2 weeks of stopping: see Case 1).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.walshe.1973.441">Walshe JM. Copper chelation in patients with Wilson&#x02019;s disease. A comparison of penicillamine and triethylene tetramine dihydrochloride. <span><span class="ref-journal">Q J Med. </span>1973;<span class="ref-vol">42</span>:441–52.</span> [<a href="/pubmed/4728043" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4728043</span></a>]<div><i>(Trientine induced a cupruresis in 18 patients with Wilson disease, which was less than with penicillamine, but was substantial particularly in patients who had never been treated, suggesting that it might be an alternative for patients intolerant to penicillamine therapy).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.siegmund.1976.172">Siegmund H. <span><span class="ref-journal">Med Welt. </span>1976;<span class="ref-vol">27</span>(4):172–3.</span> [Intrahepatic cholestasis following treatment with D-penicillamine and indomethacin] German. [<a href="/pubmed/1250131" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1250131</span></a>]<div><i>(38 year old woman with rheumatoid arthritis developed jaundice 5 weeks after starting penicillamine and indomethacin [bilirubin 5.5 mg/dL, ALT 120 U/L, Alk P 10 times ULN], jaundice resolving within 4 weeks of stopping both drugs, but Alk P remained high).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.sacher.1977.481">Sacher M, Thaler H. Toxic hepatitis after therapeutic doses of benorylate and D-penicillamine. <span><span class="ref-journal">Lancet. </span>1977;<span class="ref-vol">1</span>:481–2.</span> [<a href="/pubmed/65582" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 65582</span></a>]<div><i>(13 year old girl with rheumatoid arthritis developed jaundice 5 months after starting penicillamine with recovery in 3 months; no specifics given; benorylate is an ester of acetylsalicylic acid and acetaminophen).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.barzilai.1978.98">Barzilai D, Dickstein G, Enat R, Bassan H, Lichtig C, Gellei B. Case report: cholestatic jaundice caused by D-penicillamine. <span><span class="ref-journal">Ann Rheum Dis. </span>1978;<span class="ref-vol">37</span>:98–100.</span> [<a href="/pmc/articles/PMC1000201/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1000201</span></a>] [<a href="/pubmed/629612" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 629612</span></a>]<div><i>(56 year old man with rheumatoid arthritis developed jaundice and pruritus 4 weeks after starting penicillamine [bilirubin 15 mg/dL, ALT 203 U/L, Alk P 3 times ULN]; underwent laparotomy, with subsequent rise in bilirubin to 88 mg/dL, renal failure and death).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.mcleod.1979.965">McLeod BD, Kinsella TD. Cholestasis associated with D-penicillamine for rheumatoid arthritis. <span><span class="ref-journal">Can Med Assoc J. </span>1979;<span class="ref-vol">120</span>:965–6.</span> [<a href="/pmc/articles/PMC1819252/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1819252</span></a>] [<a href="/pubmed/436073" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 436073</span></a>]<div><i>(41 year old woman with rheumatoid arthritis developed jaundice 3 weeks after starting penicillamine [bilirubin 3.3 mg/dL, AST 117 U/L, Alk P 1132 U/L], jaundice resolving within 2 weeks and enzyme elevations within 11 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.crickx.1979.212">Crickx L, Leger JM, Auquier L. <span><span class="ref-journal">Nouv Presse Med. </span>1979;<span class="ref-vol">8</span>:212.</span> [Granulomatous hepatitis and parotiditis induced by d-penicillamine in a case of rheumatoid arthritis] French. [<a href="/pubmed/554085" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 554085</span></a>]<div><i>(50 year old woman with rheumatoid arthritis developed cholestatic jaundice and parotiditis soon after starting penicillamine, liver and parotid biopsies demonstrating granulomas; no specifics given).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.jaffe.1979.58">Jaffe IA. Penicillamine in rheumatoid arthritis: clinical pharmacology and biochemical properties. <span><span class="ref-journal">Scand J Rheumatol Suppl. </span>1979;(28):58–64.</span> [<a href="/pubmed/287192" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 287192</span></a>]<div><i>(Reports that penicillamine leads to improvements in stiffness and pain in rheumatoid arthritis after 8-12 weeks of therapy and can induce a variety of autoimmune conditions including pemphigus, myasthenia, glomerulonephritis, polymyositis, hemolytic anemia, lupus, Sj&#x000f6;gren's syndrome and thrombocytopenic purpura).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.baum.1979.65">Baum J. The use of penicillamine in the treatment of rheumatoid arthritis and scleroderma. <span><span class="ref-journal">Scand J Rheumatol Suppl. </span>1979;(28):65–70.</span> [<a href="/pubmed/377472" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 377472</span></a>]<div><i>(In review of literature on 1190 patients treated with penicillamine for 4-12 months, beneficial response rates averaged 62%, but significant side effects found in 37% of patients).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.hill.1979.94">Hill HFH. Penicillamine in rheumatoid arthritis: adverse effects. <span><span class="ref-journal">Scand J Rheumatol Suppl. </span>1979;(28):94–9.</span> [<a href="/pubmed/156393" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 156393</span></a>]<div><i>(Review of skin adverse events and fatalities due to penicillamine, deaths largely due to bone marrow toxicity; no mention of hepatotoxicity or cholestasis).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.wollheim.1979.100">Wollheim FA, Lindstr&#x000f6;m CG. Liver abnormalities in penicillamine treated rheumatoid arthritis. <span><span class="ref-journal">Scand J Rheumatol Suppl. </span>1979;(28):100–7.</span> [<a href="/pubmed/287188" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 287188</span></a>]<div><i>(Among 99 patients followed prospectively during penicillamine therapy, 6 developed serum enzyme abnormalities without jaundice, reversible within weeks of stopping in all, not always recurring with restarting penicillamine at lower doses).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.rosenbaum.1980.152">Rosenbaum J, Katz WA, Schumacher HR. Hepatotoxicity associated with use of D-penicillamine in rheumatoid arthritis. <span><span class="ref-journal">Ann Rheum Dis. </span>1980;<span class="ref-vol">39</span>:152.</span> [<a href="/pmc/articles/PMC1000500/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1000500</span></a>] [<a href="/pubmed/7387219" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7387219</span></a>]<div><i>(Two patients with rheumatoid arthritis with penicillamine hepatotoxicity; 43 year old woman developed enzyme elevations [normal bilirubin, AST 440 U/L, Alk P ~2 times ULN] without symptoms 2 months after starting penicillamine, resolving rapidly on stopping and recurring with rechallenge; 60 year old man developed jaundice 2 weeks after starting penicillamine [bilirubin 2.2 mg/dL, AST 128 U/L, Alk P 8 times ULN], resolving slowly over next 9 months).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.seibold.1981.554">Seibold JR, Lynch CJ, Medsger TA. Cholestasis associated with D-penicillamine therapy: case report and review of the literature. <span><span class="ref-journal">Arthritis Rheum. </span>1981;<span class="ref-vol">24</span>:554–6.</span> [<a href="/pubmed/7213433" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7213433</span></a>]<div><i>(26 year old woman with lupus developed fever and rash after 10 days of penicillamine which improved on stopping, but recurred after a single tablet of penicillamine with fever, rash, arthritis followed by jaundice [bilirubin 7.9 mg/dL, ALT 315 U/L, Alk P 358 U/L], resolving within 7 weeks).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.jensen.1981.3471">Jensen OH. <span><span class="ref-journal">Ugeskr Laeger. </span>1981;<span class="ref-vol">143</span>:3471–2.</span> [Penicillamine induced liver involvement] Danish. [<a href="/pubmed/7336507" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7336507</span></a>]<div><i>(64 year old man with rheumatoid arthritis developed jaundice after a year of penicillamine therapy and had sudden worsening when it was inadvertently restarted with fever and jaundice [bilirubin ~3.0 mg/dL, Alk P and AST 3 times ULN], symptoms resolving rapidly on stopping and liver tests returning to normal within 3 months).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.multz.1981.674">Multz CV. Cholestatic hepatitis caused by penicillamine. <span><span class="ref-journal">JAMA. </span>1981;<span class="ref-vol">246</span>:674–5.</span> [<a href="/pubmed/7253120" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7253120</span></a>]<div><i>(53 year old woman with rheumatoid arthritis developed jaundice 4 weeks after starting penicillamine [bilirubin 6.4 mg/dL, AST 390 U/L, Alk P 820 U/L], jaundice resolving in 2 weeks; remission in arthritis during period of jaundice).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.jobdeslandre.1982.2356">Job-Deslandre C, Delrieu F, Rondier J, Guedri M, Delbarre F. Hepatitie cholestatique et anticorps anti-DNA induits par la d-penicillamine. <span><span class="ref-journal">Nouv Presse Med. </span>1982;<span class="ref-vol">11</span>:2356–7.</span> [<a href="/pubmed/6981100" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6981100</span></a>]<div><i>(33 year old with rheumatoid arthritis treated with penicillamine for 4 years developed jaundice and lupus-like syndrome [bilirubin not given, ALT 61 U/L, Alk P 3.6 times ULN, ANA 1:500], liver abnormalities resolving within 2 months, but ANA remaining positive).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.grauer.1983.1997">Grauer JL, Fonteille J, Zarski JP, Gintz B, Phelip X, Cabanel G. <span><span class="ref-journal">Presse Med. </span>1983;<span class="ref-vol">12</span>:1997.</span> [Erythema nodosum and cholestatic hepatitis during treatment with D-penicillamine] French. [<a href="/pubmed/6225106" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6225106</span></a>]<div><i>(62 year old with rheumatoid arthritis developed fever 20 days after starting penicillamine, resolving on stopping and reappearing 2 months after restarting along with rash, but no jaundice [bilirubin not given, AST 1.5 times, Alk P 4.5 times ULN], resolving within 2 weeks of stopping again).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.emery.1984.626">Emery P, Panayi GS, Huston G, Welsh KI, Mitchell SC, Shah RR, Idle JR, et al.  D-penicillamine induced toxicity in rheumatoid arthritis : the role of sulphoxidation status and HLA-DR3. <span><span class="ref-journal">J Rheumatol. </span>1984;<span class="ref-vol">11</span>:626–32.</span> [<a href="/pubmed/6334741" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6334741</span></a>]<div><i>(Among 66 patients with rheumatoid arthritis treated with penicillamine, adverse events [largely renal, bone marrow and skin toxicities] were more common in those with low sulphoxidation indices [60%] than in those with normal values [17%], and with HLA DR3 [60% vs 29%], without interaction of the two predictive factors).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.gefel.1985.303">Gefel D, Hrats N, Lijovetsky G, Eliakim M. Cholestatic jaundice associated with d-penicillamine therapy. <span><span class="ref-journal">Scand J Rheumatol. </span>1985;<span class="ref-vol">14</span>:303–6.</span> [<a href="/pubmed/4048879" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4048879</span></a>]<div><i>(35 year old man with cystinuria developed fever and rash 16 days after starting penicillamine followed by jaundice [peak bilirubin 14.9 mg/dL, ALT 149 U/L, Alk P 553 U/L], biopsy showing intrahepatic cholestasis; prednisone was started when bilirubin worsened; jaundice resolved within 3 months and abnormal Alk P within 9 months of stopping).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.devogelaer.1985.35">Devogelaer JP, Huaux JP, Coche E, Rahier J, Nagant de Deuxchaisnes C. A case of cholestatic hepatitis associated with D-penicillamine therapy for rheumatoid arthritis. <span><span class="ref-journal">Int J Clin Pharmacol Res. </span>1985;<span class="ref-vol">5</span>:35–8.</span> [<a href="/pubmed/3997313" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3997313</span></a>]<div><i>(72 year old man with rheumatoid arthritis developed pruritus and jaundice 1 month after starting penicillamine [bilirubin 16.2 mg/dL, ALT 227 U/L, Alk P 290 U/L], jaundice resolving within 3 weeks and serum enzymes within 6 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.abadia.1985.590">Abadia R, Jammet P, Christoforov B, Cremer GA. <span><span class="ref-journal">Ann Med Interne (Paris). </span>1985;<span class="ref-vol">136</span>:590–600.</span> [Hepatotoxicity of drugs commonly used in rheumatology] [<a href="/pubmed/2868682" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2868682</span></a>]<div><i>(Review of hepatotoxicity of rheumatologic agents; mentions 16 cases of penicillamine induced liver injury, typically with immunoallergic features and cholestatic pattern with resolution in 2-4 weeks, recurrence after reexposure in 5 instances; one fatality).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.kumar.1985.337">Kumar A, Bhat A, Gupta DK, Goel A, Malaviya AN. D-penicillamine-induced acute hypersensitivity pneumonitis and cholestatic hepatitis in a patient with rheumatoid arthritis. <span><span class="ref-journal">Clin Exp Rheumatol. </span>1985;<span class="ref-vol">3</span>:337–9.</span> [<a href="/pubmed/4085166" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4085166</span></a>]<div><i>(45 year old woman with rheumatoid arthritis developed rash, fever and hypersensitivity pneumonitis 10 days after starting penicillamine, responding to prednisone therapy but with subsequent jaundice [peak bilirubin 30 mg/dL, ALT 300 U/L, Alk P 5 times ULN], resolving within 4 weeks of stopping; recurrence of dyspnea and jaundice after unintentional rechallenge).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.choudhuri.1986.299">Choudhuri G, Tandon RK. D-penicillamine induced cholestatic jaundice. <span><span class="ref-journal">J Assoc Physicians India. </span>1986;<span class="ref-vol">34</span>:299–300.</span> [<a href="/pubmed/3759835" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3759835</span></a>]<div><i>(45 year old woman with rheumatoid arthritis developed rash, fever and dyspnea within 2 weeks of starting penicillamine [initial bilirubin 7.0 mg/dL, ALT 200 U/L, Alk P 5 times ULN]; allergic alveolitis responding rapidly to prednisone, but bilirubin rising to 30 mg/dL; positive rechallenge; appears to be same patient as described by Kumar [1985]).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.roux.1986.21">Roux H, Bonnefoy-Cudraz M, Antipoff GM. <span><span class="ref-journal">Rev Rhum Mal Osteoartic. </span>1986;<span class="ref-vol">53</span>:21–3.</span> [Liver complications caused by D-penicillamine. Apropos of a case] French. [<a href="/pubmed/3704507" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3704507</span></a>]<div><i>(60 year old woman with rheumatoid arthritis developed rash and pruritus followed by jaundice 6 weeks after starting penicillamine [bilirubin 8.2 mg/dL, ALT 61 U/L, Alk P 2158 U/L, 14% eosinophilia], resolving slowly upon stopping).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.scheinberg.1987.209">Scheinberg IH, Jaffe ME, Sternlieb I. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease. <span><span class="ref-journal">N Engl J Med. </span>1987;<span class="ref-vol">317</span>:209–13.</span> [<a href="/pubmed/3600712" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3600712</span></a>]</div></li><li><div class="bk_ref" id="Penicillamine.REF.cooperative_systemic_studies_of_rheumatic_disease_group.1987.67">Cooperative Systemic Studies of Rheumatic Disease Group.  Toxicity of longterm low dose D-penicillamine therapy in rheumatoid arthritis. <span><span class="ref-journal">J Rheumatol. </span>1987;<span class="ref-vol">14</span>:67–73.</span> [<a href="/pubmed/2952797" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2952797</span></a>]<div><i>(Among 148 patients with rheumatoid arthritis continued on long term penicillamine, side effects included rash, gastrointestinal upset, proteinuria, bone marrow suppression, myasthenia, myositis, drug fever and pemphigus; no late hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.moens.1987.1115">Moens HJ, Ament BJ, Feltkamp BW, van der Korst JK. Longterm followup of treatment with D-penicillamine for rheumatoid arthritis: effectivity and toxicity in relation to HLA antigens. <span><span class="ref-journal">J Rheumatol. </span>1987;<span class="ref-vol">14</span>:1115–9.</span> [<a href="/pubmed/3437418" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3437418</span></a>]<div><i>(HLA testing done on 86 patients with rheumatoid arthritis started on penicillamine including 22 on long term [5-7 years] therapy; HLA-DR4 was associated with thrombocytopenia [94% vs 67%] and HLA-B8/DR3 with proteinuria [60% vs 9%], but no association with effectiveness; no cases of hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.berbis.1987.377">Berbis P, Fabre JF, Privat Y. <span><span class="ref-journal">Ann Dermatol Venereol. </span>1987;<span class="ref-vol">114</span>:377–9.</span> [Cholestatic hepatitis: a rare complication of the treatment with D. penicillamine] French. [<a href="/pubmed/3605968" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3605968</span></a>]<div><i>(22 year old woman with scleroderma developed fever, rash, and weakness followed by jaundice 10 days after starting penicillamine [bilirubin 1.5 mg/dL, ALT 381 U/L, Alk P 409 U/L with mild eosinophilia], resolving within 3 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.guerrero_navarro.1988.221">Guerrero Navarro L, Molina Lorente E, Mur Villacampa M, Revillo Pinilla P. <span><span class="ref-journal">Rev Esp Enferm Apar Dig. </span>1988;<span class="ref-vol">73</span>:221.</span> [Cholestatic hepatitis caused by D-penicillamine] Spanish. [<a href="/pubmed/3375535" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3375535</span></a>]<div><i>(61 year old man developed fever, rash, pruritus and jaundice 3 days after starting penicillamine [peak bilirubin 10.6 mg/dL, ALT 198 U/L, Alk P 336 U/L], resolving within 2 weeks).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.fishel.1989.609">Fishel B, Tishler M, Caspi D, Yaron M. Fatal aplastic anaemia and liver toxicity caused by d-penicillamine treatment of rheumatoid arthritis. <span><span class="ref-journal">Ann Rheum Dis. </span>1989;<span class="ref-vol">48</span>:609–10.</span> [<a href="/pmc/articles/PMC1003826/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1003826</span></a>] [<a href="/pubmed/2774703" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2774703</span></a>]<div><i>(65 year old woman with rheumatoid arthritis developed thrombocytopenia 3 months after starting penicillamine [platelet count 10,000/&#x000b5;L, white cell count 3000/&#x000b5;L, hemoglobin 6.7 gm/dL] and subsequently developed jaundice [bilirubin 10.0 mg/dL, AST 80 U/L, Alk P 120 U/L], dying 17 days later with bone marrow, renal and hepatic failure).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.jacobs.1994.770">Jacobs JW, Van der Weide FR, Kruijsen MW. Fatal cholestatic hepatitis caused by D-penicillamine. <span><span class="ref-journal">Br J Rheumatol. </span>1994;<span class="ref-vol">33</span>:770–3.</span> [<a href="/pubmed/8055207" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8055207</span></a>]<div><i>(37 year old woman with rheumatoid arthritis developed fever, granulocytopenia and jaundice 10 days after starting penicillamine [without rash or eosinophilia], with intrahepatic cholestasis on liver biopsy and subsequent persistent jaundice and cholestasis and death from sepsis 14 months later).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.barthel.1995.1253">Barthel HR, Hiepe F. <span><span class="ref-journal">Dtsch Med Wochenschr. </span>1995;<span class="ref-vol">120</span>:1253–7.</span> [Lupus erythematosus and liver diseases] German. [<a href="/pubmed/7671785" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7671785</span></a>]<div><i>(Review of liver abnormalities in lupus erythematosus; penicillamine can induce a lupus-like syndrome which resolves when the drug is stopped, although ANA positivity may persist).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.harders.1977.10">Harders H, Cohnen E. Preparation of and clinical experiences with trien for the treatment of Wilson&#x02019;s disease in absolute intolerance of D-penicillamine. <span><span class="ref-journal">Proc R Soc Med. </span>1977;<span class="ref-vol">70</span> Suppl 3:10–2.</span> [<a href="/pmc/articles/PMC1543601/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1543601</span></a>] [<a href="/pubmed/122652" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 122652</span></a>]<div><i>(28 year old woman who was intolerant to penicillamine was successfully treated with trientine prepared by an improved method, with prompt cupruresis and improvement in neurologic symptoms).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.chalasani.2008.1924">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J., Drug Induced Liver Injury Network (DILIN).  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, none were attributed to penicillamine).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.roberts.2008.2089">Roberts EA, Schilsky ML. AASLD. Diagnosis and treatment of Wilson disease: an update. <span><span class="ref-journal">Hepatology. </span>2008;<span class="ref-vol">47</span>:2089–111.</span> [<a href="/pubmed/18506894" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18506894</span></a>]<div><i>(Thorough review of the cause, natural history, diagnosis and treatment of Wilson disease with specific recommendations for use of penicillamine, trientine and zinc).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.walshe.2009.2289">Walshe JM. The conquest of Wilson's disease. <span><span class="ref-journal">Brain. </span>2009;<span class="ref-vol">132</span>(Pt 8):2289–95.</span> [<a href="/pubmed/19596747" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19596747</span></a>]<div><i>(History of the initial description of Wilson disease, its link to copper accumulation, and therapies several of which were developed by the author).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.weiss.2012.1">Weiss KH, Stremmel W. Evolving perspectives in Wilson disease: diagnosis, treatment and monitoring. <span><span class="ref-journal">Curr Gastroenterol Rep. </span>2012;<span class="ref-vol">14</span>(1):1–7.</span> [<a href="/pubmed/22083169" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22083169</span></a>]<div><i>(Review of the diagnosis and management of Wilson disease, including the role of genetic testing and the choice of medical therapies).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.weiss.2013.1028">Weiss KH, Thurik F, Gotthardt DN, Sch&#x000e4;fer M, Teufel U, Wiegand F, Merle U, et al.  EUROWILSON Consortium. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. <span><span class="ref-journal">Clin Gastroenterol Hepatol. </span>2013;<span class="ref-vol">11</span>:1028–35.e1.</span> [<a href="/pubmed/23542331" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23542331</span></a>]<div><i>(Retrospective analysis of 380 patients with Wilson disease from referral centers in Germany and Austria, including 141 who were treated with trientine and 326 with penicillamine, found similar rates of improvement in liver disease but higher rate of improvement in neurologic features with penicillamine, along with higher rates of adverse events leading to discontinuation [29% vs 7%], although there were no therapy related deaths; reasons for discontinuation in the penicillamine group included arthralgias, gastrointestinal upset, myalgias, leukopenia, rash, lupus erythematosus and increase in ANA titers; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.hern_ndez.2014.231">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A, Chirino R, et al.  Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:231–9.</span> [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, none of which was attributed to penicillamine or other agents used to treat Wilson disease).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, one case was attributed to penicillamine in a woman with scleroderma who developed fatigue, jaundice and rash 3 weeks after starting penicillamine [bilirubin 5.6 rising to 10.5 mg/dL, ALT 308 U/L, Alk P 377 U/L], resolving slowly and with persistent, mild elevations in ALT and Alk P during long term follow up).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.pfeiffenberger.2018.1261">Pfeiffenberger J, Beinhardt S, Gotthardt DN, Haag N, Freissmuth C, Reuner U, Gauss A, et al.  Pregnancy in Wilson's disease: management and outcome. <span><span class="ref-journal">Hepatology. </span>2018;<span class="ref-vol">67</span>:1261–9.</span> [<a href="/pubmed/28859232" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28859232</span></a>]<div><i>(Among 282 pregnancies in 136 patients with Wilson disease analyzed in a retrospective, multicenter study, spontaneous abortion was less common among patients being treated with penicillamine [17%] or zinc [10%] than untreated patients [41%], which was proportionally greater than with trientine [28%] and similar to that in patients who discontinued therapy during pregnancy [36%]; worsening of liver disease arose in some patients on treatment but was self-limiting and resolved after delivery; birth defects were found in 7 of 209 [3%] newborns overall and in 4 of 98 women taking penicillamine).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.roberts.2018.56">Roberts EA. Update on the diagnosis and management of Wilson disease. <span><span class="ref-journal">Curr Gastroenterol Rep. </span>2018;<span class="ref-vol">20</span>:56.</span> [<a href="/pubmed/30397835" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30397835</span></a>]<div><i>(Review of recent advances in the understanding of the pathogenesis, clinical features, diagnosis, and treatment of Wilson disease).</i></div></div></li><li><div class="bk_ref" id="Penicillamine.REF.appenzellerherzog.2019.2136">Appenzeller-Herzog C, Mathes T, Heeres MLS, Weiss KH, Houwen RHJ, Ewald H. Comparative effectiveness of common therapies for Wilson disease: A systematic review and meta-analysis of controlled studies. <span><span class="ref-journal">Liver Int. </span>2019;<span class="ref-vol">39</span>:2136–52.</span> [<a href="/pubmed/31206982" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31206982</span></a>]<div><i>(Systematic review of literature on therapies of Wilson disease found no differences in outcomes with penicillamine vs zinc, but higher rates of adverse events and discontinuations with penicillamine; no mention of hepatotoxicity or ALT elevations).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548246</span><span class="label">PMID: <a href="/pubmed/31643570" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643570</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Penbutolol/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/PenicilllinGandV/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548246&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548246/?report=reader">PubReader</a></li><li><a href="/books/NBK548246/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548246" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548246" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Penicillamine. [Updated 2020 Jul 25].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548246/pdf/Bookshelf_NBK548246.pdf">PDF version of this page</a> (136K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(penicillamine/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%222010/4/01%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Penicillamine: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=penicillamine" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Penicillamine: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4862222" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4862222" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4862222" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23605177" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Penicillamine revisited: historic overview and review of the clinical uses and cutaneous adverse effects.</a><span class="source">[Am J Clin Dermatol. 2013]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Penicillamine revisited: historic overview and review of the clinical uses and cutaneous adverse effects.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ishak R, Abbas O. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Clin Dermatol. 2013 Jun; 14(3):223-33. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31644190" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Wilson Disease Agents</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Wilson Disease Agents<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/6958210" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis.</a><span class="source">[Ann Intern Med. 1982]</span><div class="brieflinkpop offscreen_noflow">Systemic lupus erythematosus during penicillamine therapy for rheumatoid arthritis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Chalmers A, Thompson D, Stein HE, Reid G, Patterson AC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Ann Intern Med. 1982 Nov; 97(5):659-63. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/3752071" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Penicillamine-induced rapidly progressive glomerulonephritis in patients with progressive systemic sclerosis: successful treatment of two patients and a review of the literature.</a><span class="source">[Am J Kidney Dis. 1986]</span><div class="brieflinkpop offscreen_noflow">Penicillamine-induced rapidly progressive glomerulonephritis in patients with progressive systemic sclerosis: successful treatment of two patients and a review of the literature.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ntoso KA, Tomaszewski JE, Jimenez SA, Neilson EG. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Kidney Dis. 1986 Sep; 8(3):159-63. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/6993073" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Hidden anti-nuclear antibodies in rheumatic diseases.</a><span class="source">[Clin Exp Immunol. 1980]</span><div class="brieflinkpop offscreen_noflow">Hidden anti-nuclear antibodies in rheumatic diseases.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mach PS, Piatier D, Le Go A, Delbarre F. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Exp Immunol. 1980 Feb; 39(2):538-43. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643570" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643570" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60468e169e31203af6af1251">Penicillamine - LiverTox</a><div class="ralinkpop offscreen_noflow">Penicillamine - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T15:50:31-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal106&amp;ncbi_phid=CE8D209D046645F100000000093302B8&amp;ncbi_session=CE8D209D0468E151_2355SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548246%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548246&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548246/&amp;ncbi_pagename=Penicillamine - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D209D0468E151_2355SID /projects/books/PBooks@9.2 portal106 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>